Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint

Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2021) Stephen M Ansell et al.   CLINICAL CANCER RESEARCH

Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells

(2021) Gabriela Andrejeva et al.   JOURNAL OF IMMUNOLOGY

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance

(2020) Vanessa Gauttier et al.   JOURNAL OF CLINICAL INVESTIGATION

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

(2019) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

(2019) O Hamid et al.   ANNALS OF ONCOLOGY

Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding

(2019) Robyn J. Puro et al.   MOLECULAR CANCER THERAPEUTICS

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint

(2019) Erik Voets et al.   Journal for ImmunoTherapy of Cancer

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

(2018) Caroline Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy

(2018) André Veillette et al.   TRENDS IN IMMUNOLOGY

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

(2018) Steven E. Kauder et al.   PLoS One

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy targeting the CD47/SIRPα axis

(2017) Kipp Weiskopf   EUROPEAN JOURNAL OF CANCER

New checkpoints in cancer immunotherapy

(2017) Ling Ni et al.   IMMUNOLOGICAL REVIEWS

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer

(2017) Hanke L. Matlung et al.   IMMUNOLOGICAL REVIEWS

SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin

(2017) Jun Chen et al.   NATURE

Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity

(2017) Nan Guo Ring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis

(2016) Lu Gao et al.   Oncotarget

“Velcro” Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein α (SIRPα) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis

(2015) Chia Chi M. Ho et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

(2015) Stefano Ugel et al.   JOURNAL OF CLINICAL INVESTIGATION

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

(2015) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

Polymorphisms in the Human Inhibitory Signal-regulatory Protein α Do Not Affect Binding to Its Ligand CD47

(2014) Deborah Hatherley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

(2013) D. Tseng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD47-signal regulatory protein-  (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction

(2011) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Self inhibition of phagocytosis: The affinity of ‘marker of self’ CD47 for SIRPα dictates potency of inhibition but only at low expression levels

(2010) Richard K. Tsai et al.   BLOOD CELLS MOLECULES AND DISEASES

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

(2010) M. P. Chao et al.   Science Translational Medicine

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells

(2008) Richard K. Tsai et al.   JOURNAL OF CELL BIOLOGY